Biologit founder Nicole Baker believes automation will become increasingly important for screening scientific literature. Immunologist Nicole Baker has more than two decades of experience in academia, pharma regulation and clinical research. While working in the biotech and pharma industry, Baker specifically worked in the area of pharmacovigilance, which involves reviewing the vast number of medical extracts published each year as well as, increasingly, forums such as social media, to identify any red flags regarding adverse effects of drugs on the market. Using this extensive knowledge, she went on to create Biologit, an artificial intelligence start-up that aims to help keep patients safe by simplifying the detection of adverse events from drug development to post-market. It does this by automating the task of monitoring scientific literature. "I have always been interested in science, but also on how to best use technology to help with new discoveries and on our day-to-day activities," Baker told Siliconrepublic.com.

The proportion of pharmaceutical companies hiring for artificial intelligence related positions dropped in October 2022 compared with the equivalent month last year, with 37.4% of the companies included in our analysis recruiting for at least one such position. This latest figure was lower than the 38.6% of companies who were hiring for artificial intelligence related jobs a year ago and a decrease compared to the figure of 39.8% in September 2022. When it came to the rate of all job openings that were linked to artificial intelligence, related job postings dropped in October 2022 from September 2022, with 7% of newly posted job advertisements being linked to the topic. This latest figure was an increase compared to the 3.3% of newly advertised jobs that were linked to artificial intelligence in the equivalent month a year ago. Artificial intelligence is one of the topics that GlobalData, from whom our data for this article is taken, have identified as being a key disruptive force facing companies in the coming years.

I want to sometimes cover the academic news-cycle around more academic or technical type of A.I. news and I think this will be the Newsletter publication where I will do that as opposed to AISupremacy. So for more Academic dealings of machine-learning, subscribe to Data Science Learning Center. This Newsletter was actually born from being defrauded by a site called Datascience Central, a supposed client who refused to pay me for eight articles I wrote in the second half of 2021. Microsoft has invented a method to on-board deep learning more efficiently into drug discovery. FS-MOL essentially brings deep learning in Early-Stage Drug Discovery.

By 2023, the pharmaceutical industry is projected to increase up to $1.5 trillion dollars. Throughout the past years, there has been huge growth within the Pharma industry that will continue into 2022. Artificial Intelligence (AI) is becoming a universal term in many industries today. AI uses learned machine intelligence to perform tasks and make predictions. AI within the pharma industry has many purposes that can accelerate the discovery and development of new drugs.

We previously discussed the role of artificial intelligence within the drug discovery and clinical trial process. Let's break down how AI plays a role in commercialization and the different ways AI can be implemented into the marketing processes to effectively and quickly get new products to market. In a white paper written by Pratap Khedkar and Saby Mitra, AI is attributed to boosting pharmaceutical sales through customer affinity prediction, customer journey design, next best actions and suggestions, patient switch propensity and adherence, KOL mapping and influence networks. Customer affinity prediction uses AI by collecting data from individuals to predict whether they would be interested in a product. They target them with advertisements through a multitude of channels with a prediction accuracy rate as high as 85%.

The pharma industry is seeing an increase in artificial intelligence (AI) investment across several key metrics, according to an analysis of GlobalData data. AI is gaining an increasing presence across multiple sectors, with top companies completing more AI deals, hiring for more AI roles and mentioning it more frequently in company reports at the start of 2021. GlobalData's thematic approach to sector activity seeks to group key company information on hiring, deals, patents and more by topic to see which companies are best placed to weather the disruptions coming to their industries. These themes, of which AI is one, are best thought of as "any issue that keeps a CEO awake at night", and by tracking them it becomes possible to ascertain which companies are leading the way on specific issues and which are dragging their heels. According to this method, Novartis, GlaxoSmithKline, Merck & Co are classed as dominant players in AI in the sector, with an additional 19 companies classified as leaders.

Artificial Intelligence has played an increasingly important role within the pharmaceutical space especially with recent restrictions due to COVID-19. The drug development process can be lengthy and costly but many companies have begun implementing AI into their clinical trials to speed up patient on-site visits, test efficacy and bring more drugs to market. As we discussed previously, AI has played an important role in the discovery process. Now let's take a look at AI in clinical trials… PRNewswire reports the global virtual clinical trials market size is expected to reach 11.5 billion USD by 2028 with a compound annual growth rate of 5.7% from 2021 to 2028 according to Grand View Research, Inc. The growth in the virtual clinical trial space is directly related to the need for an increase in patient diversity and an increase in the number of decentralized/virtual trials due to the impact of COVID-19.

Amongst the most significant trends to watch out for in the pharma industry in 2021 is how consumer behaviour has witnessed a significant acceleration towards e-consultations through live video calls between doctors and patients, e-purchases of medicines by uploading doctor's e-prescriptions, and home-collection of blood samples. At the same time, the combined power of the Internet, data science, connected devices and AI have expedited the pace of digital transformation in pharma organisations to improve quality and productivity. Skilled manpower in artificial intelligence (AI), machine learning (ML), cloud computing, robotic process automation (RPA), and other technological areas are helping speed up drug repurposing and development of biomarkers. Al algorithms, Big Data and early-stage experiments using new technologies are helping substantially lower time and costs in bringing new drug formulations to market. The entire research and development cycle spanning data management, clinical trials and testing are now so technology oriented that pharma companies are increasingly on boarding'health-tech' partners and tech start-ups in the journey to drug discovery, hitherto a pure science domain.

It's almost difficult to talk about the future of any industry without referencing artificial intelligence (AI). Increasingly, pharma and biotech organizations are embracing more effective, automated processes that integrate data-driven decisions and utilize predictive analytics tools. The next development of this approach to deal with cutting-edge data analytics fuses machine learning and AI. The absolute most discussed issues incorporate drug deficiencies, clinical trials, and the opioid epidemic, all within the difficulties of the COVID-19 pandemic. Despite the fact that these issues appear to be inauspicious and huge, AI is deliberately positioned to help us better address all challenges.

Artificial Intelligence is a rapidly growing technology that finds applications and uses cases in all aspects of industry and life as well: within smart factories that use AI technology to enhance their capabilities and in smart assistants found in smart phones. Similarly, the pharmaceutical industry is finding innovative and smart ways to use this modern technology to resolve some of the significant issues facing pharma sector today. Along with AI-powered analytics, big data has brought a radical shift in the paradigm of the pharma. Artificial intelligence has the potential to promote innovation, while at the same time increasing productivity and providing better results. In addition, Artificial Intelligence develops the value proposition of pharmaceutical companies by creating new and latest business models.